What Real-World Data Shows About Using the Omnipod 5 Automated Insulin Pump

The Omnipod 5 is an automated insulin delivery system—meaning it combines an insulin pump, continuous glucose monitor (CGM), and algorithm to deliver insulin automatically based on blood sugar readings. While clinical trials showed promising results, researchers wanted to see how it actually performs when thousands of people use it outside a study setting.

A 2024 study published in Diabetes Technology & Therapeutics analyzed data from nearly 70,000 Omnipod 5 users in the United States with at least 90 days of use. This real-world evidence reveals how well the system works for different ages, prior therapies, and insulin targets in everyday life.

One of the most important measures of diabetes management is time in range (TIR)—the percentage of time your blood sugar stays between 70 and 180 mg/dL. In the large Omnipod 5 study, median time in range varied based on the glucose target users selected.

Users who set their target to 110 mg/dL achieved a median TIR of 68.8%. Those targeting 120 mg/dL reached 61.3%, and those aiming for 130–150 mg/dL achieved 53.6%. Importantly, time spent below 70 mg/dL (a level considered too low) remained minimal across all groups—all medians stayed below 1.13%.

When researchers looked specifically at users targeting 110 mg/dL, they found that children and adolescents (ages 2–17) had a median TIR of 65%, while adults 18 and older achieved 69.9%. This suggests the system performs consistently across age groups, though individual results will vary.

The study found that younger users more commonly selected multiple glucose targets and higher target ranges, while older users tended to choose lower targets. This likely reflects different family preferences and individual management approaches.

The research also examined people transitioning from other therapies. Some users were switching from the Omnipod DASH (an earlier pump model without automation), while others came from multiple daily injections (MDI)—taking insulin several times per day with a pen or syringe. The system worked effectively for people from both backgrounds.

One practical detail: during virtual training, users learn that the Omnipod pod and Dexcom CGM need to maintain line of sight to communicate wirelessly. Wearing them on opposite arms is acceptable, so users have flexibility in where they place the devices.

Several automated insulin delivery systems are now available to people with type 1 diabetes. A 2024 systematic review compared different systems—including the Omnipod 5, Minimed 780G, Minimed 670G, and Control-IQ—by analyzing randomized clinical trials.

The review found that all automated systems significantly increased time in range compared to standard insulin therapy without a CGM. When ranking systems by their ability to increase time in range, the Minimed 780G performed highest, followed by Control-IQ, Minimed 670G, and others. However, all systems successfully reduced time below target range and maintained similar safety profiles for severe low blood sugar and diabetic ketoacidosis.

Research on Omnipod 5 continues. A decentralized observational registry is currently recruiting users to gather long-term real-world data on safety and effectiveness in children and adults with type 1 diabetes. These ongoing studies help clinicians and users understand how the technology performs over time and in diverse populations.

Origin: YouTube / Mary Comeau (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.